Care Capital

CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

BioCritica is a biotechnology company dedicated to addressing critical care needs in the hospital market, particularly focusing on severe sepsis treatment with its product, Xigris. The company is actively developing a pipeline of additional products aimed at enhancing patient outcomes and supporting clinicians. BioCritica's mission centers on creating and commercializing innovative solutions that significantly improve the quality of life for patients facing critical health challenges.

Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.

NormOxys, Inc. is a biotechnology company focused on developing small molecule drugs for oncology treatment, particularly through its lead product, OXY111A, an effective anti-cancer drug. Founded in 2003 and based in Boston, Massachusetts, NormOxys specializes in proprietary therapies that regulate the binding affinity between oxygen and hemoglobin, enhancing the body's ability to deliver oxygen to diseased tissues. This innovative approach allows for the administration of non-toxic drugs to patients. The company was previously known as Oxyplus, Inc. before rebranding in October 2008.

Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of oral recombinant protein vaccines using its proprietary vaccine platform. The company is focused on creating oral vaccines that can generate broad and durable immune responses against various infectious diseases. Its product pipeline includes an oral tablet vaccine for norovirus, which has completed Phase I clinical trials, a seasonal influenza vaccine currently in Phase II trials, and vaccines targeting respiratory syncytial virus and coronavirus. Additionally, Vaxart is developing therapeutic vaccines for human papillomavirus-related conditions. The company aims to improve vaccination rates by offering a convenient, room temperature-stable tablet format, which is easier to distribute and administer compared to traditional injectable vaccines. Vaxart also has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform for a universal influenza vaccine program.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

MicroCHIPS Biotech, Inc. specializes in developing a microchip-based implant designed for drug delivery applications across various therapeutic areas, including osteoporosis, diabetes, multiple sclerosis, women’s contraception, and pain management. This innovative implant can store and release precise doses of medication over extended periods, offering an alternative to traditional therapies that rely on frequent injections. The implant is surgically placed under the skin during a minimally invasive procedure and can be wirelessly activated or deactivated by healthcare providers or patients. Additionally, the device allows for real-time adjustments to the drug dosage and frequency, catering to the specific needs of each patient. Established in 1999 and headquartered in Lexington, Massachusetts, MicroCHIPS operates as a subsidiary of Daré Bioscience, Inc.

Anacor Pharmaceuticals is a biopharmaceutical company that specializes in discovering, developing, and commercializing small-molecule therapeutics based on its boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis of the toenails. Its lead candidate, crisaborole topical ointment, is currently in Phase III clinical trials aimed at addressing mild-to-moderate atopic dermatitis and psoriasis. Additionally, Anacor is developing AN3365, an antibiotic for infections caused by Gram-negative bacteria. The company has established collaboration agreements with various organizations to explore new treatments for diseases such as African trypanosomiasis, tuberculosis, and Chagas disease. Anacor Pharmaceuticals, which was incorporated in 2000 and is headquartered in Palo Alto, California, previously operated under the name AnaMax, Inc. It has been a subsidiary of Pfizer since June 2016.

CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

NephroGenex is a drug-development company focusing on kidney disease. The Company is developing Pyridorinâ„¢ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.

ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

Cardiokine, Inc. is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing pharmaceuticals aimed at preventing and treating cardiovascular diseases. Founded in 2004, the company is known for its lead product, lixivaptan, an orally active vasopressin receptor antagonist designed for patients with congestive heart failure who experience hyponatremia. Cardiokine is committed to advancing innovative therapies to address heart failure and related cardiovascular conditions.

MPV is committed to improving business processes throughout the healthcare revenue cycle, resulting in increased efficiency and lower costs for medical groups, payers, employers and, ultimately, for patients. From improving payer contract management processes to verifying insurance and benefits to generating an accurate estimate of a patient's out-of-pocket expenses, MPV is your partner of choice. Their Web-based revenue cycle solutions enable providers to collect the right payment from the right party in the shortest amount of time, resulting in improved financial performance and a stronger bottom line.

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Anacor Pharmaceuticals is a biopharmaceutical company that specializes in discovering, developing, and commercializing small-molecule therapeutics based on its boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis of the toenails. Its lead candidate, crisaborole topical ointment, is currently in Phase III clinical trials aimed at addressing mild-to-moderate atopic dermatitis and psoriasis. Additionally, Anacor is developing AN3365, an antibiotic for infections caused by Gram-negative bacteria. The company has established collaboration agreements with various organizations to explore new treatments for diseases such as African trypanosomiasis, tuberculosis, and Chagas disease. Anacor Pharmaceuticals, which was incorporated in 2000 and is headquartered in Palo Alto, California, previously operated under the name AnaMax, Inc. It has been a subsidiary of Pfizer since June 2016.

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Cardiokine, Inc. is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing pharmaceuticals aimed at preventing and treating cardiovascular diseases. Founded in 2004, the company is known for its lead product, lixivaptan, an orally active vasopressin receptor antagonist designed for patients with congestive heart failure who experience hyponatremia. Cardiokine is committed to advancing innovative therapies to address heart failure and related cardiovascular conditions.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapeutic aptamers for the prevention and treatment of various chronic and acute diseases. Established in 2000, the company’s notable product candidate is ARC1779, aimed at treating thrombotic microangiopathies and supporting carotid endarterectomy surgical procedures. In addition to this, Archemix is involved in developing other aptamer-based therapeutics targeting diseases in the fields of cardiovascular health, hematology, and oncology.

Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.

ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

Renovo is a biopharmaceutical product company specializing in the development of drugs to reduce scarring, improve wound healing, and enhance tissue regeneration. With a focus on addressing the unmet market need for scar reduction pharmaceuticals in the US and Europe, Renovo is advancing a pipeline that includes one drug in phase 3 clinical development, two drugs in phase 2 clinical development, and several pre-clinical candidates. As a leader in this space, Renovo is dedicated to bringing innovative solutions to market to improve patient outcomes and quality of life.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapeutic aptamers for the prevention and treatment of various chronic and acute diseases. Established in 2000, the company’s notable product candidate is ARC1779, aimed at treating thrombotic microangiopathies and supporting carotid endarterectomy surgical procedures. In addition to this, Archemix is involved in developing other aptamer-based therapeutics targeting diseases in the fields of cardiovascular health, hematology, and oncology.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.